SHRXF (Sharp Therapeutics) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHRXF Sharp Therapeutics Corp SHRXF
12 GF Score
Price $0.57
View Full Analysis

What is Sharp Therapeutics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sharp Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1.23 Mil. Sharp Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1.03 Mil. Sharp Therapeutics's annualized EBITDA for the quarter that ended in Jun. 2026 was $0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sharp Therapeutics's Debt-to-EBITDA or its related term are showing as below:

SHRXF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.57   Med: -0.44   Max: -0.22
Current: -0.38

During the past 3 years, the highest Debt-to-EBITDA Ratio of Sharp Therapeutics was -0.22. The lowest was -2.57. And the median was -0.44.

SHRXF's Debt-to-EBITDA is ranked worse than
100% of 305 companies
in the Biotechnology industry
Industry Median: 1.24 vs SHRXF: -0.38

Sharp Therapeutics  (OTCPK:SHRXF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Sharp Therapeutics Debt-to-EBITDA Related Terms

Sharp Therapeutics Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Debt-to-EBITDA Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Debt-to-EBITDA
-2.57 -0.44 -0.22

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 0.52 -0.32 -0.14 N/A

SHRXF vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Sharp Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sharp Therapeutics Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sharp Therapeutics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sharp Therapeutics's Debt-to-EBITDA falls into.


SHRXF
12GF Score
Sharp Therapeutics Corp SHRXF
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sharp Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.109 + 1.174) / -5.909
=-0.22

Sharp Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.225 + 1.033) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
12GF Score

Get the complete analysis for SHRXF

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price